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alcohol consumption, in whom NAFLD was diagnosed by non
enhanced CT and were compared to 33 healthy controls matched
for age, and BMI. Tissue Doppler echocardiography (TDI) was
performed in all patients.
Results: Patients with NAFLD were male (95% VS 72%, P< 0.01) and
had increased mean systolic blood pressure (140±14 VS 132±14,
P < 0.02) than controls. NAFLD patients had lower early diastolic
tissue velocity (e′ on TDI, 10.2±2.9 cm/sec vs. 12.2±3.1 cm/s,
P < 0.011), lower ratio of early diastolic to late diastolic mitral inflow
(E/A ratio 1.12±0.4 vs 1.42±0.35, P < 0.28), higher atrial reversal
velocity of mitral inflow (Ar velocity 28±6 vs 25±4.4, p < 0.03),
higher left ventricle mass (156±30 VS 137±31, p < 0.013), higher
deceleration time (DT 208.2±40 ms vs 184.2±26, P < 0.004), and
higher short axis mediastinal fat (SAX 6.7±2.9mm vs. 5.1±2.6,
P < 0.019) than healthy controls. All of these differences remained
significant after adjustment for hypertension and other cardio
metabolic risk factors. Pericardial fat thickness, left ventricular
volumes, ejection fraction, and relation time (IVRT) were not
different.
Conclusions: Our data show that patients with NAFLD have early
features of LV diastolic dysfunction.
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PREDICTIVE VALUE OF EPICARDIAL FAT AS NEW MARKER OF
METABOLIC SYNDROME AND EARLY VASCULAR DAMAGE IN
PATIENT WITH NAFLD
O.N. Korneeva, O.M. Drapkina, V.T. Ivashkin. Internal Disease, I.M.
Sechenov First Moscow State Medical University, Moscow, Russia
E-mail: doctorok@land.ru
Background: Increased visceral adiposity is considered the
hallmark of the metabolic syndrome (MS) and Non-alcoholic fatty
liver disease (NAFLD). Epicardial adipose tissue has been implicated
in the pathogenesis of coronary atherosclerosis.
Aim: To evaluate in patients with MS and NAFLD the threshold
values of echocardiographic epicardial fat thickness and their
association with a) metabolic and clinical parameters, b)
early atherosclerotic vascular damage, by carotid intima media
thickness (IMT).
Methods: 41 patients with MS and with clinic, laboratory,
ultrasound, histology proven NAFLD were enrolled in the study
(20 men, age 48±13 years, BMI 33±5kg/m2, waist circumference
(men) 114±11 cm, (women) 109±10 cm) and 20 controls without
MS and without NAFLD (11 men, age 47±9 years BMI 23±1kg/m2).
Physical examination, blood tests, carotid ultrasound were
performed. Epicardial fat thickness was evaluated by transthoracic
echocardiogram.
Results: Patients with MS and NAFLD had significantly higher
epicardial fat thickness than controls (4.95±2.6 and 2.69±1.8mm,
p =0.01). Considering as increased values higher than 2.7mm
(median of controls) we evaluated variables associated with
increased epicardial fat. Age, BMI, waist circumference, fasting
glucose, HOMA-IR, IMT were significantly higher in subjects with
increased epicardial fat than without, while the echocardiographic
diastolic function index early/atrial peak flow (E/A) was
significantly lower. At multivariate analysis HOMA-IR remained the
independent variable associated with epicardial fat (p = 0.04, OR1.8,
95%CI1.037–3.58).
Conclusion: In conclusion patients with MS and NAFLD had higher
value of epicardial fat thickness than controls, the increased
epicardial fat values were associated with insulin-resistant and
with early vascular damage. Epicardial fat measurement, an easy
diagnostic tool to define visceral and cardiac adiposity could be
proposed to better predict the cardiovascular risk and connection
with NAFLD.
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GASTRIC BYPASS IS EFFICIENT ON MEBOLIC AND LIVER
STEATOSIS AFTER LAPAROSCOPIC GASTRIC BANDING RELAPSE
G. Lassailly1,2, R. Caiazzo3,4, D. Buob5, A. Louvet1,2, F. Artru1,2,
S. Dharancy1,2, V. Canva-Delcambre1, P. Deltenre1, F. Pattou3,4,
P. Mathurin1,2. 1Department of Hepatology, CHRU Lille, 2INSERM 995,
Lille 2 University, 3Department of General and Endocrine Surgery,
CHRU Lille, 4INSERM 859, Lille 2 University, 5Department of Pathology,
CHRU Lille, Lille, France
E-mail: guillaume.lassailly@gmail.com
For some morbid obese patients the benefit of gastric banding (GB)
appears insufficient in terms of BMI and insulin resistance (IR)
decrease. It is not known whether a switch to gastric bypass (GBP)
may be propose in such patients.
Aims:
1. To evaluate the evolution of patients considered as having an
insufficient response to GB.
2. To determine effectiveness of the switch to GBP in such patients
in term of BMI, insulin resistance and liver injury.
Methods: In a prospective database, 573 morbidly obese treated
with GB were included. Clinical, histological and biological
parameters (IR measured as 1/QUICKI) were recorded. Less-
responder patients (LR) were treated at their request by GBP after
exhaustive and careful selection.
Results:
1. Among 573 patients, 48 patients had a second line with GBP
for insufficient response. 525 were not considered for a second
line as response was considered as satisfactory by patient and
physician.
LR Patients treated by GBP were not significantly different at
baseline form the 525 in terms of: age (39.8 vs 40.2 years),
steatosis (30 vs 25%), NAS≥3 (27.3 vs 27.3%), cholesterol (5.2 vs
5mmol/l) GGT (26 vs 30 IU/l), IR (3.1 vs 3.1). Whereas LR patients
were significantly different for BMI (47 vs 45.1 kg/m2 p=0.005),
ALT (21 vs 26 p=0.03), triglycerid (1.6 vs 1.4 p =0.03).
Insufficient response to therapy was confirmed by the fact that
steatosis score and IR return close to the value observe at
baseline. Whereas the other had a lower amount of steatosis
3%, IR 2.83 at five years (p = 0.004).
2. The evolution of patients after the switch for GBP, LR patient
treated with GBP observe a improvement in BMI (−18% p=0.003),
decrease in IR from 2.94 to 2.7 p =0.003, steatosis from 30% to 5%
p < 0.05. The benefit was sustained at 5 years as shown by a lower
steatosis (1%) and IR (2.64) (p < 0.05 as compared to baseline).
Conclusion: Fat amount and IR return to baseline values in LR
patients. Switch to GBP seems to restore response to bariatric
surgery. These data support the need for alternative strategy to GB.
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CONTRIBUTION OF VISCERAL FAT AND HEPATIC FAT TO
METABOLIC DERANGEMENTS AND LIVER DAMAGE IN NAFLD
PATIENTS
L. Mezzabotta1, E. Vanni1, C. Rosso1, S. Carenzi1, R. Gambino2,
M. Gaggini3, D. Lucarelli4, R. Faletti4, M. Cassader2, A. Smedile1,
M. Rizzetto1, A. Gastaldelli3, E. Bugianesi1. 1Division of Gastro-
Hepatology, Department of Internal Medicine, 2Lab. of Diabetology,
Department of Internal Medicine, San Giovanni Battista Hospital,
University of Torino, Torino, 3Cardiometabolic Risk Unit, Institute
of Clinical Physiology, CNR, Pisa, 4Radiology, San Giovanni Battista
Hospital, University of Torino, Torino, Italy
E-mail: laviniaemme@hotmail.com
Background and Aims: Both hepatic and visceral fat have been
implicated in the onset and progression of metabolic syndrome
and NAFLD. However, their relative role is still debated. Aim of this
study was to determine the relative contribution of hepatic and
visceral fat to both metabolic derangements and histological liver
damage in subjects with biopsy-proven NAFLD.
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Methods: In 22 non-diabetic, non-dyslipidaemic patients with
biopsy-proven NAFLD we measured whole abdomen visceral fat
(VF) by MRI, fasting endogenous glucose production (EGP) and
lipolysis by tracer infusion, peripheral insulin resistance (IR) as
HOMA, Hepatic-IR as EGP x fasting insulin, and adipose tissue
(Adipo)-IR as basal FFA levels x fasting insulin. Hepatic histology
was scored according to Kleiner, liver fat was also reported as
percentage (LF%).
Results: In our study cohort, VF was increased in proportion to
BMI (r = 0.54, p < 0.004) and to LF%, (r = 0.43, p < 0.03), whereas LF%
was not correlated with BMI. Only LF%, but not VF, was associated
with circulating FFA levels (r = 0.51, p < 0.01), and Adipo-IR (r = 0.41,
p < 0.05), while no correlation was found between either LF% or VF
with Hepatic-IR or HOMA.
Patients with NAS score ≥4 (compared to those with NAS 0–3)
had more VF (3.9±0.7 vs 2.8±0.4 kg), increased FFA concentrations
(525±52 vs 804±98mmol/l), peripheral IR (HOMA: 3.7±0.5 vs
2.8±0.8), hepatic-IR (169±23 vs 124±32), and adipose-IR (13.2±2.5
vs 6.3±1.8) (all p < 0.05). When taking into account only balloning
and lobular inflammation in the NAS score, we found that subjects
with a composite score >2 had an impaired suppression of
lipolysis.
Compared to patients without fibrosis, those with fibrosis had more
VF (3.9±0.6 vs 2.7±0.7 kg, p < 0.03), but not LF%, and no differences
were found in the indexes of IR.
Conclusions: In NAFLD subjects, liver fat is associated with
metabolic derangements and insulin resistance, but insulin
resistance of the adipose tissue and VF accumulation appear to
provide a major contribution to liver damage.
Funding from the FP7/2007–2013 under grant agreement no.
Health-F2–2009–241762, for the FLIP project.
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INTEROBSERVER CONCORDANCE IN CONTROLLED ATTENUATION
PARAMETER (CAP) MEASUREMENT, A NOVEL TOOL FOR THE
ASSESSMENT OF HEPATIC STEATOSIS BASED ON TRANSIENT
ELASTOGRAPHY
E. Recio1, K. Neukam1, C. Cifuentes1, M. Mancebo1, J. Macı́as1,
C. Almeida2, N. Merchante1, J.A. Mira1, A. Rivero-Juárez3,
J.A. Pineda1. 1Unit of Infectious Diseases and Microbiology, 2Unit
of Investigation, Hospital Universitario de Valme, Seville, 3Unit of
Infectious Diseases, Maimonides Institute for Biomedical Research
(IMIBIC), Hospital Universitario Reina Sof́ıa, Cordoba, Spain
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Introduction: The combination of transient elastometry (TE)
with controlled attenuation parameter (CAP) allows non-invasive
measurements of hepatic steatosis (HS) simultaneously to liver
stiffness. TE is characterized by a high reproducibility and low inter-
observational variability in HCV-infected patients with or without
HIV coinfection. Nevertheless, no data are available on interobserver
differences in CAP values. This is a relevant point, since HS is a very
common disorder among HIV-infected patients, and accurate non-
invasive diagnosis is critical.
Objective: To assess the concordance of CAP measurements
between two independent observers in patients infected with HIV
and/or hepatitis virus.
Methods: In a cross-sectional, prospective study conducted from
December 2011 to March 2012 in a university hospital in Spain,
CAP-enabled TE acquisitions were performed by two independent
observers in 118 consecutive patients with HIV and/or hepatitis
virus infection. The interobserver concordance between the CAP
value measurements was assessed using the intraclass correlation
coefficient (ICC) and the concordance of the classification of
patients regarding the grades of HS was characterized using the
kappa index. Patients with CAP ≥238 dB/m were considered to bear
significant HS (≥10% hepatocytes involved), as previously reported.
Results: 78% patients were male. Twenty (17%) patients were HIV
monoinfected, 44 (37.3%) hepatitis C virus (HCV)-monoinfected and
52 (44%) showed HIV/HCV coinfection. The median (Q1-Q3) values
of CAP obtained by the first and the second observer were 228 (205–
265) and 227 (196–269) dB/m, respectively. The median (interquar-
tile range) of the absolute difference of CAP values between the two
observers was 20 (10–41) dB/m. The overall ICC was 0.84 (95% con-
fidence interval: 0.77–0.88). The kappa index for the concordance of
classification for the presence of significant HS was 0.55. No factor
was associated with a greater concordance between observers.
Conclusions: The concordance of CAP values obtained by two
observers is good. Therefore, the determination of HS by means
of CAP in HIV and/or hepatitis virus infection represents an
observer-independent and easily performable method. However,
the concordance of the diagnosis of significant HS, defined by the
cutoff of 238 dB/m, is suboptimal.
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(PUFA) FROM FISH AND FLAXSEED OILS ON NONALCOHOLIC
STEATOHEPATITIS (NASH)
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Introduction: There are very few intervention strategies that have
been proven in non-alcoholic fatty liver disease (NAFLD). Omega-3
polyunsaturated fatty acids (PUFA) seem to be efficacious on
NAFLD treatment from experimental models, but few randomized
trails have been realized. The aim of this study was to evaluate
prospectively the efficacy of Omega-3 PUFA derived from fish and
flaxseed in non-alcoholic steatohepatitis (NASH) patients.
Methods: Sixty patients with biopsy proven NASH were included
in the randomized placebo controlled trial. The patients were
randomized into two groups. Omega-3 group (n =30) received
capsules containing 945mg of Omega-3 PUFA [a linolenic
acid/64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic
acid (DHA)/21%], in 3 capsules/day. Placebo Group (n =30), received
3 placebo capsules containing mineral oil. The intervention was
carried out for 6 months, when patients were re-submitted for
new liver biopsy. Primary endpoint was liver histology according
to the NASH activity score (NAS) at baseline and 6 months. Second
endpoints were evaluated by analysis of serum aminotransferases,
fasting lipid profile, serum glucose, anthropometric parameters and
serum levels of cytokines at 0, 3 and 6 months.
Results: These 60 patients enrolled, 10 were not finished the study
(5 in Omega-3 group and 5 in the Placebo group). Concerning
the primary endpoint, the NAS activity improved by 57% in
the placebo group and 67% in the omega-3 group, however,
no significant difference was seen (p =0.33), the hepatocellular
ballooning reduced 22% in the placebo group and 33% in the
omega-3 group, also with no difference between groups (p = 0.28).
Omega-3 did not reduce steatosis, lobular inflammation and
fibrosis. Serum aminotransferases, fasting lipid profile, serum
glucose, anthropometric parameters and serum levels of IL-6 and
TNF-a were not altered with the treatment.
Conclusion: Our results indicate that Omega-3 PUFA from fish
and flaxseed oil compound cannot improve, after 6 months, the
liver histology, biochemical parameters and serum levels of IL-6
and TNF-a. The limitations of this study were the small number
of patients enrolled and the composition of Omega-3 compound
that was enriched with linolenic acid (64%) than EPA/DHA. Further
study is needed to confirm these results.
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